Gossamer Bio (NASDAQ: GOSS)
Gossamer Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gossamer Bio Company Info
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.
News & Analysis
Why Gossamer Bio Stock Is Tumbling Today
Stock dilution is on the way for the small biotech.
Why Gossamer Bio Stock Is Crashing Today
Novartis is throwing in the towel on a drug similar to Gossamer's lead candidate.
Is Gossamer Bio a Buy?
Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.
Why Gossamer Bio Stock Is Swinging Wildly Today
Investors weren't exactly sure how to react to the clinical failure of a drug that works similarly to Gossamer's lead candidate.
Are Biotech IPOs A Good Investment?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.